MedPath

CLinical EValuation of WEB 0.017 Device in Intracranial AneuRysms

Completed
Conditions
Brain Aneurysm
Registration Number
NCT03844334
Lead Sponsor
Microvention-Terumo, Inc.
Brief Summary

The study is an observational, European, multi-center, prospective assessment of the clinical utility of the 0.017 WEB Aneurysm Embolization System in subjects with intracranial aneurysms deemed appropriate for endovascular treatment.

Detailed Description

All eligible subjects presenting to the participating Centers will be considered for entry into the study. Up to 160 evaluable subjects meeting the study entry criteria will be enrolled.

Subjects will be followed per Institution's standard of care.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
163
Inclusion Criteria
  1. Subject must be ≥ 18 years of age and ≤80 years of age
  2. Subject must have an intracranial aneurysm (IA),
  3. Subject must sign and date Ethics Committee approved written informed consent prior to initiation of any clinical interventional procedures or when applicable, register the patient non opposition to the study data collection
  4. For ruptured aneurysm, Subject with Hunt & Hess Score ≤ III
Exclusion Criteria
  1. Subject has an IA with characteristics unsuitable for endovascular treatment
  2. Subject's index IA was previously treated
  3. Subject has stroke-in-evolution within the prior 30 days
  4. An additional aneurysm must be treated during the procedure

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Aneurysm occlusion12 months

Angiographic (conventional Angio) occlusion based on Raymond-Roy occlusion scale The Raymond-Roy occlusion classification (RROC) is an angiographic classification scheme for grading the occlusion of endovascularly treated intracranial aneurysms.

* class I: complete obliteration

* class II: residual neck

* class III: residual aneurysm

Incidence of major stroke or neurological deaths12months

The proportion of subjects with death of any nonaccidental cause or any major stroke within the first 30 days after treatment or major ipsilateral stroke or death due to neurologic cause from day 31 to the 1 year after treatment

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

Universitätsklinikum Knappschaftskrankenhaus

🇩🇪

Bochum, Germany

Hôpital Purpan

🇫🇷

Toulouse, France

National Institute of Clinical Neurosciences

🇭🇺

Budapest, Hungary

Hôpital Bicêtre

🇫🇷

Le Kremlin-Bicêtre, France

© Copyright 2025. All Rights Reserved by MedPath